Effects of a Nutraceutical Preparation on Cognitive Impairment in Hypertensive Patients
NCT ID: NCT02572219
Last Updated: 2017-03-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
12 participants
INTERVENTIONAL
2015-11-30
2016-11-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
CMI-168 on Cognitive Function in Healthy Middle-aged Men and Women
NCT03612752
Acute Effect of a Standardized Botanical Blend Rich in Polyphenols on Cognitive Functions in Healthy Students
NCT03508206
Effect of a Specific Phenolic Compound on Blood Pressure
NCT02628353
Impact of Resveratrol on Brain Function and Structure
NCT02621554
Effect of a Nootropic on the Cognitive Performance in Young Adults
NCT04790188
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Nutraceutical
Treated with nutraceutical compound
Nutraceutical compound
Placebo
Treated with placebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Nutraceutical compound
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Males or females between 40 and 65 years of age;
* Hypertensive patients classified according to their SBP (Systolic Blood Pressure) and DBP (Diastolic Blood Pressure) values. Included patients will be those with stage 1 hypertension (SBP 140-159 mmHg; DBP 90-99 mmHg) and with stage 2 hypertension (SBP 160-179 mmHg; DBP 100-109 mmHg).
Exclusion Criteria
* Previous stroke and/or transient ischemic attack (TIA);
* Diabetes mellitus;
* History of atrial fibrillation or other severe arrhythmias;
* Severe cardiovascular diseases;
* Renal pathologies (creatinine \> 1.4 mg/dL);
* Preexisting psychiatric pathologies;
* Neurodegenerative diseases, such as multiple sclerosis, lateral amyotrophic sclerosis, Parkinson, Alzheimer, neuromuscular pathologies, epilepsy;
* Diagnosis of dementia;
* Depression;
* Long-term regular use of anxiolytics drugs, antidepressant drugs, antipsychotic drugs, hypnoinducing drugs, cognitive stimulators.
40 Years
65 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Neuromed IRCCS
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Giuseppe Lembo
prof. Giuseppe Lembo
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
IRCCS Neuromed
Pozzilli, (is), Italy
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
LMB04
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.